BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Auxogyn, Inc. Completes $20 Million in Series A Funding


2/2/2012 7:57:50 AM

MENLO PARK, Calif., Feb. 2, 2012 /PRNewswire via COMTEX/ -- Auxogyn, Inc., a privately-held company focused on advancing women's reproductive health, today announced the close of the final tranche of its Series A financing, bringing the total funding to $20 million. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures.

"Over the course of the last year, we have executed an aggressive operating plan in preparation for the commercialization of our first product, Eeva. Importantly, we expect to announce data from our five-site, 150-patient clinical study in the months ahead that will then be used as part of our regulatory filings in Europe and the United States," said Lissa Goldenstein, president and chief executive officer of Auxogyn.

"In evaluating investments throughout the medical technology field, we were impressed with Auxogyn's unique approach of bringing scientific rigor and data analytics backed by a robust intellectual property portfolio and top-tier clinical advisors to a market in desperate need of improved results," said Mark Gudiksen, Ph.D., principal of TPG Biotech and member of Auxogyn's board of directors.

"As the leader in fertility, Merck Serono is committed to investing in innovative technologies to improve the chance of a successful IVF pregnancy," said Nilesh Kumar Ph.D., director, Merck Serono Ventures. "This investment reflects our confidence in achieving this goal."

"Having developed its first product, initiated a substantive clinical study, and built a sound organizational infrastructure, Auxogyn has set the stage for an exciting 2012, springboarding toward commercialization in the latter half of the year," said Beth Seidenberg, M.D., partner at Kleiner Perkins Caulfield and Byers and a member of the Auxogyn board of directors.

About Eeva(TM)Auxogyn's non-invasive early embryo viability assessment (Eeva) system may improve IVF outcomes by providing IVF clinicians and patients with objective information on embryo viability. Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters. With Eeva's quantitative data on each embryos' potential development, IVF clinicians can optimize the treatment path for their patients undergoing IVF procedures.

About Kleiner Perkins Caufield & ByersSince its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in more than 500 ventures including AOL, Amazon.com, Citrix, Compaq, Electronic Arts, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Sun, Symantec, Verisign, WebMD and Zynga. KPCB portfolio companies employ more than 350,000 people worldwide. More than 150 of the firm's portfolio companies have gone public, and many other KPCB ventures have achieved success through mergers and acquisitions. KPCB focuses its global investments in three practice areas - digital, greentech and life sciences - and provides entrepreneurs with company-building expertise out of its offices in Silicon Valley, Beijing and Shanghai.

About TPG BiotechTPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm. With more than $1 billion under management, TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology. TPG Biotech's investments in personalized medicine and genomics have included such companies as Genomic Health, XDx, CardioDx and Veracyte. Please visit www.tpgbiotech.com .

About Merck Serono VenturesMerck Serono Ventures is the strategic, corporate venture capital fund of Merck Serono, the division for biopharmaceuticals of Merck KGaA. The fund invests in emerging biotechnology companies with the potential to provide breakthrough medical solutions in Merck Serono's focus therapeutic areas: Oncology, Neurodegenerative Diseases, Rheumatology, Fertility and Endocrinology. In addition, Merck Serono Ventures invests in companies developing innovative technologies that could enable the discovery and development of new products in its core therapeutic areas. For more information, visit www.merckserono.com

About Auxogyn

Auxogyn, Inc. is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The company's first product, Early Embryo Viability Assessment (Eeva), provides quantitative information regarding embryo development, to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, TPG Biotech and Merck Serono Ventures. For more information regarding Auxogyn please visit www.auxogyn.com .

SOURCE Auxogyn, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES